Compare Dishman Pharma with SHASUN PHARMA - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DISHMAN PHARMA vs SHASUN PHARMA - Comparison Results

DISHMAN PHARMA     Change

Dishman Pharmaceuticals is involved in the manufacture of APIs (active pharmaceutical ingredients), intermediates, quaternary compounds and fine chemicals. Besides this, the company is a significant player in the CRAMS (Contract Research and Manufact... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DISHMAN PHARMA SHASUN PHARMA DISHMAN PHARMA/
SHASUN PHARMA
 
P/E (TTM) x 25.1 123.9 20.2% View Chart
P/BV x 3.3 8.5 39.2% View Chart
Dividend Yield % 0.7 0.2 284.9%  

Financials

 DISHMAN PHARMA   SHASUN PHARMA
EQUITY SHARE DATA
    DISHMAN PHARMA
Mar-16
SHASUN PHARMA
Mar-14
DISHMAN PHARMA/
SHASUN PHARMA
5-Yr Chart
Click to enlarge
High Rs37494 397.5%   
Low Rs12946 282.7%   
Sales per share (Unadj.) Rs197.8214.2 92.4%  
Earnings per share (Unadj.) Rs21.25.3 397.4%  
Cash flow per share (Unadj.) Rs34.715.8 219.5%  
Dividends per share (Unadj.) Rs2.001.00 200.0%  
Dividend yield (eoy) %0.81.4 55.6%  
Book value per share (Unadj.) Rs179.953.3 337.2%  
Shares outstanding (eoy) m80.6956.62 142.5%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x1.30.3 389.8%   
Avg P/E ratio x11.913.1 90.6%  
P/CF ratio (eoy) x7.24.4 164.0%  
Price / Book Value ratio x1.41.3 106.8%  
Dividend payout %9.418.7 50.3%   
Avg Mkt Cap Rs m20,3063,958 513.1%   
No. of employees `0000.8NA-   
Total wages/salary Rs m5,3552,164 247.5%   
Avg. sales/employee Rs Th19,252.7NM-  
Avg. wages/employee Rs Th6,459.5NM-  
Avg. net profit/employee Rs Th2,064.1NM-  
INCOME DATA
Net Sales Rs m15,96112,127 131.6%  
Other income Rs m265229 115.7%   
Total revenues Rs m16,22612,356 131.3%   
Gross profit Rs m4,1031,009 406.6%  
Depreciation Rs m1,091594 183.7%   
Interest Rs m944415 227.5%   
Profit before tax Rs m2,334230 1,015.9%   
Minority Interest Rs m00-   
Prior Period Items Rs m10 -366.7%   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m624-73 -857.5%   
Profit after tax Rs m1,711302 566.4%  
Gross profit margin %25.78.3 309.0%  
Effective tax rate %26.7-31.7 -84.4%   
Net profit margin %10.72.5 430.3%  
BALANCE SHEET DATA
Current assets Rs m11,0186,884 160.0%   
Current liabilities Rs m9,5178,456 112.5%   
Net working cap to sales %9.4-13.0 -72.6%  
Current ratio x1.20.8 142.2%  
Inventory Days Days11062 179.3%  
Debtors Days Days35108 32.4%  
Net fixed assets Rs m16,3044,970 328.0%   
Share capital Rs m161113 142.5%   
"Free" reserves Rs m12,9072,875 448.9%   
Net worth Rs m14,5163,020 480.6%   
Long term debt Rs m4,1891,817 230.5%   
Total assets Rs m29,80513,347 223.3%  
Interest coverage x3.51.6 223.5%   
Debt to equity ratio x0.30.6 48.0%  
Sales to assets ratio x0.50.9 58.9%   
Return on assets %8.95.4 165.8%  
Return on equity %11.810.0 117.8%  
Return on capital %17.513.3 131.6%  
Exports to sales %24.846.4 53.5%   
Imports to sales %3.714.2 26.2%   
Exports (fob) Rs m3,9565,622 70.4%   
Imports (cif) Rs m5961,728 34.5%   
Fx inflow Rs m4,9525,843 84.7%   
Fx outflow Rs m6972,173 32.1%   
Net fx Rs m4,2553,669 115.9%   
CASH FLOW
From Operations Rs m2,786398 700.8%  
From Investments Rs m-1,529-1,635 93.5%  
From Financial Activity Rs m-9411,309 -71.9%  
Net Cashflow Rs m31671 444.4%  

Share Holding

Indian Promoters % 61.4 39.2 156.6%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 3.7 3.6 102.8%  
FIIs % 12.7 17.6 72.2%  
ADR/GDR % 0.0 0.0 -  
Free float % 22.1 39.6 55.8%  
Shareholders   46,261 20,750 222.9%  
Pledged promoter(s) holding % 35.8 12.3 291.0%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DISHMAN PHARMA With:   PFIZER  GSK PHARMA  PANACEA BIOTECH  WYETH  ABBOTT INDIA  

Compare DISHMAN PHARMA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Zooms 661 Points, Nifty Ends Above 14,500; M&M and Bajaj Finserv Top Gainers(Closing)

Indian share markets witnessed most of the buying interest during closing hours today and ended on a strong note.

Related Views on News

Most Popular

India: Recovery Stalled by Vaccine Games?(The Honest Truth)

Apr 13, 2021

Ajit Dayal on how India's vaccine strategy will impact the markets.

4 Stocks to Make Your Portfolio Immune to the Second Covid Wave(Profit Hunter)

Apr 6, 2021

Rather than predicting the market, successful investing is more about preparing well and placing your bets accordingly.

If the Market Falls, I Will Do This...(Fast Profits Daily)

Apr 1, 2021

What should you do if the market falls? In this video, I'll tell you what I will do.

The Indian Real Estate Party Has Just Begun(Profit Hunter)

Apr 1, 2021

A favourable demand supply scenario makes a strong case for real estate prices.

The Dilemma of Investing in Bharti Airtel(Views On News)

Apr 1, 2021

Rahul Shah on whether Bharti Airtel will emerge as the next big thing in the Indian stock market

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

DISHMAN PHARMA SHARE PRICE


May 29, 2017 (Close)

TRACK DISHMAN PHARMA

  • Track your investment in DISHMAN PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON DISHMAN PHARMA

DISHMAN PHARMA 5-YR ANALYSIS

COMPARE DISHMAN PHARMA WITH

MARKET STATS